Calamos Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Calamos Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17,449	Closed	-$266K	–	1243
2022 Q3	$266K	Buy	+17,449	New	+$289K	﹤0.01%	1040

Other funds holding AXDX

GAM

Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Calamos Advisors's AXDX Position: Q4 2022 in Review

Calamos Advisors sold out of Accelerate Diagnostics (AXDX) in Q4 2022, closing a stake of 17,449 shares — an estimated $266K sold.

Calamos Advisors first reported a position in AXDX in Q3 2022 and held it in 1 quarter. The position peaked at $266K in Q3 2022. 72 funds tracked by Wall St. Rank hold AXDX as of Q4 2022.

Calamos Advisors reported no remaining Accelerate Diagnostics position as of Q4 2022 after selling out during the quarter.
Calamos Advisors sold 17,449 Accelerate Diagnostics shares in Q4 2022, an estimated $266K.
Calamos Advisors first reported a position in Accelerate Diagnostics in Q3 2022 and held it in 1 quarter.
Calamos Advisors's Accelerate Diagnostics position peaked at $266K in Q3 2022.
72 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2022.

Based on Calamos Advisors's 13F filing for Q4 2022, filed 26 Jan 2023.